Due to COVID-19 situation, CABS Board of Directors have decided to postpone CABS 2020 BioPacific Conference to May 8th, 2021 (Saturday). The conference venue will be the same: San Mateo Marriott Hotel. The election of 2020 CABS President-elect, Executive Council (EC) and transition of CABS presidency will also be postponed from September, 2020 to September, 2021. Current CABS President, President-elect and EC team will stay on duty until September, 2021. 

CABS community's health and safety is our No.1 priority. We are one of the first professional organizations national-wide to cancel large social gathering events in anticipating the potential outbreak of Coronavirus infection back to January of this year. Postponing 2020 BioPacific Conference is a continuation of our policy to safeguard our community.

Current CABS EC team has been working together as a unified force to combat COVID-19 and serve our community. The team's willingness to serve for one more year is a testament of our strength and commitment to you during this crisis. CABS will continue leading our community efforts to combat COVID-19 and to provide more online forums to share the latest development in COVID-19 diagnostics and treatment and also in other areas of drug discovery. 

For sponsors and exhibitors who have already committed to 2020 CABS BioPacific Conference, your reserved sponsorship/exhibitor spots will be carried over to 2021 conference. As an appreciation of your support at this critical moment, we will continue promoting your company brand names to our community from now until the end of 2021. There are still spots left for sponsor/exhibitors of 2021 BioPacific Conference. If interested, please contact fundraising@cabsweb.org for details. 

A big thank-you to speakers/panelists who have already accepted our invitation to present at 2020 BioPacific Conference. We hope you are available for 2021 Conference on May 8th, 2021. CABS volunteers will reach out to you for details. 

Finally, we sincerely thank 2019-2020 term CABS EC members and volunteers,  for your team efforts in combating COVID-19 and your commitment to serve CABS for two years. Your efforts and diligent work will be special and important to our community. 

Sincerely and Best

CABS Board of Directors and President


Dear guests of BioPacific Toastmasters Club,

We at the BioPacific Toastmasters club would like to invite you to join our first-ever virtual open house!

The theme of this special edition of open house is "Take Me Home, Country Roads". Everyone is encouraged to set your Zoom virtual background to something related to your hometown OR some objects you have that are related to your hometown, and everyone will have a chance to talk about it in the table topics session.

The open house will be held on Saturday, September 26th, from 6:00 to 7:15 PM. It will feature a prepared speech, an extended table topics session, and social time for the guests and members to get to know about each other as well as the club. The Zoom meeting link will be provided to the registered guests.

Please check out the attached flyer for more information. The registration link is https://forms.gle/bz1kUzAfv6ncB1xG9, which is also available in the flyer as a QR code.

New to Toastmasters? Check out https://www.toastmasters.org/membership/why-toastmasters for a great introduction.

Interested in our club? Visit https://biopacific.toastmastersclubs.org/

Zoom Conference

CABS Webinar

Leverage Global Clinical Resources for Drug Development

US Pacific Time: September 25 (Friday), 2020, 2:00pm-4:00pm

How to Perform Early Stage Trials in US

China Drug Regulatory Reform and Include China in Next Trial

Manage Global Clinical Trials During COVID-19 Pandemic

Webinar is Free and No Registration Required

Join Webinar through Zoom:


Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)


(This event will be broadcast to you through Zoom Conference; agenda is based on US Pacific Time)

2:00pm - 2:05pm Introduction to CABS, Dr. Yang Tian, President of CABS

2:05pm - 2:40pm Phase I Clinical Trials in the USA – Maximizing Value, Managing Risk. Lisa E. Diamond, PhD, President, Frontage Clinical Services.

2:40pm - 3:15pm Including China into Your Drug Development Strategy: Why, When, and How. Jiansong Yang, PhD, CSO and SVP, Tigermed

3:15pm - 3:50pm China’s significant role in the handling of COVID-19 global pandemic. Melika Davis, MS, VP, and Le Dao, BS, PMP, Associate Director, BeiGene

3:50pm - 4:10pm Panel Discussion


Lisa E. Diamond, PhD, President, Frontage Clinical Services

As President of Frontage Clinical Services since 2018, Dr. Diamond provides oversight for Clinical Study Conduct and Analyses, Client Relations, and Business Development activities.

Dr. Diamond joined Frontage as Director of Clinical Affairs in 2005, was Vice-President of Clinical Affairs and Project Management in 2009-2013, and rejoined Frontage in 2017 as Vice-President of Clinical Affairs, US and China. In these positions she managed cross-functional teams, including Data Management, Programming, Biostatistics, Project Management and Medical Writing, provided Clinical Operations oversight and supported Business Development and Client Relations. Her prior positions in academia, small biopharmaceutical companies, Palatin Technologies, DNX and Nextran (1989-2005) and at Bristol-Myers Squibb (2013-2017), contribute to a broad experience base in research and development, preclinical and clinical research, a detailed knowledge of GCP/ICH guidelines, and a solid background in oncology, immunology, diabetes, autoimmune disease and transplantation research.

Dr. Diamond earned her Doctor of Philosophy and Master of Science degrees in Basic Medical Sciences from New York University (New York, Ny), and her Bachelor of Science degree from Suffolk University (Boston, MA). She completed her post-doctoral training at Princeton University (Princeton, NJ), and is an adjunct professor at Rider University (Lawrenceville, NJ).

Jiansong Yang, PhD, CSO&SVP, Tigermed

Dr. Jiansong Yang is the Chief Scientific Officer of Tigermed, which is the largest clinical CRO in China. He’s also the Founder and CEO of Mosim (now a Tigermed company), where he leads a team of over 100 scientists focusing on drug development strategy, clinical study design and PK/PD data analysis.

Dr Yang has over 15 years of experience in the pharmaceutical industry, specialized in early drug development and clinical study design. Prior to Mosim, he was Director of Clinical Pharmacology at GSK. He received his Ph.D. on Clinical Pharmacokinetics from the University of Sheffield, UK.

Melika Davis, MS, Vice President,BeiGene

Melika is the VP of Global Clinical Operations at BeiGene and leads a team of about 400 associates around the world, responsible for the planning and execution of all Clinical Trials’ activities.

Melika has 15 years of senior management experience and 25 years of Clinical Research and Development Quality Assurance experience.  Through designing and building successful global organizations, Melika and her teams have brought, on the worldwide market, 20+ products in the last 10 years, mainly in Oncology, Vaccines, and Anti-Infectives. Melika has led teams up to 700+ associates in Clinical Monitoring Operations and managed a portfolio up to 1,500 clinical trials a year.

Prior to joining BeiGene, Melika held numerous positions at Novartis and Schering Plough Research Institute of increasing responsibilities across the Research and the Development organizations in the areas of Oncology, Transplant, Anti-Infective, Respiratory, and Vaccines.

Melika holds a Master’s degree in Molecular Biology from Texas Women’s University in Dallas, Texas and a License de Physiologie from the University of Sciences in Nice, France.

Le Dao, BS, PMP, Associate Director, BeiGene

Le is an Associate Director of Portfolio and Program Management at BeiGene and is responsible for management of clinical programs in early stage development. She has 20+ years of clinical development experience and PM expertise that includes team management, business insights, clinical pharmacology (PK/PD) and combination product development across multiple disease areas, including oncology/CIT, immunology, and infectious disease. She has a strong record of collaboration across multidisciplinary functions in building and delivering on strategic plans. In addition to her technical industry expertise, she is passionate about making a meaningful difference in patients’ lives, community building, and leadership development.

Le holds a Bachelor’s degree in Chemistry from University of California, Los Angeles.

Webinar is Free and No Registration Required

Join Webinar through Zoom:


Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)

Zoom Conference

Free Online Symposium: Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond

Date/Time: Sept 17 & 18, 2020; 8:30 - 12:00 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx

Online Webinar through Zoom Conference

Antibody Drug Conjugates Seminar

On August 29, 2020, the Chinese American Biopharmaceutical Society (CABS) successfully hosted a webinar on Antibody Drug Conjugates (ADCs).

With the accelerated approval of Trodelvy in 2020, nine antibody drug conjugates now on the market have truly proven their potential. During the webinar, five experts from Seattle Genetics, Sutro Biopharma, Genentech, and Eli Lilly delved into the pioneering development of ADC from its early discovery to manufacturing CMC and clinical study. The speakers also emphasized the recent application of the ADC in fields other than oncology.

The webinar attracted more than 200 attendees from the biotech and pharmaceutical communities.


Dr. Ken Zhang, Co-Chair of Science and Technology Committee of CABS, kicked off the webinar with an introduction of CABS and Science Committee’s previous events.

Dr. Kristin Bedard, Vice President of Immuno-biology of Sutro Biopharma, started with the first talk on “Antibody Drug Conjugates - Using a Novel Technology to Produce First in Class Immune Modulating Cancer Drugs”. Dr. Bedard introduced Sutro’s proprietary technology on ADCs production in a cell free environment for rapid screening of lead candidates. She showed lead ADC molecule STRO-002 with its in vitro and in vivo activity and strong synergism with checkpoint blockades such as PD-L1. “One advantage of STRO-002 is its dual functions; it kills tumor cells through immunogenic cell death and releases tumor antigens that can further stimulate anti-tumor immunity”. The second story Dr. Bedard shared was about ADC development combining of a novel toll-like receptor (TLR) agonist and a traditional cytotoxic antibody drug conjugate warhead. It demonstrated more complete anti-tumor effects in preclinical tumor models and protective T cell mediated immunity. “This novel ADC technology can not only reduce tumor burden through direct killing but can also stimulate a protective and adaptive immune response against the tumor”, Dr. Bedard concluded her talk. 


Dr. Chunze Li, Director/Principal Scientist/Group Leader at Genentech, presented the second talk on “Clinical Pharmacology Strategies in Supporting Drug Development and Approval of Antibody Drug Conjugates”. Dr. Li started her talk with an overview of ADC design concept, i.e., to increase the therapeutic window of cytotoxic agents. She highlighted a few major challenges in ADC design. Dr. Li presented an overview of clinical pharmacology strategy to support the development and approval of an ADC. Specifically, she provided a few examples to illustrate the unique clinical pharmacology consideration for ADCs, including bioanalytical strategies, PK and ADME characterizations, exposure-response analysis to inform dose selection and strategy to support dose recommendation in specific population (e.g., patients with renal and hepatic impairment).